Low Baseline Interleukin-17A Levels Are Associated with Better Treatment Response at 12 Weeks to Tocilizumab Therapy in Rheumatoid Arthritis Patients

Circulating Th17 and Th1 cells expressing CD161 are associated with disease activity in rheumatoid arthritis

(2014) J Miao et al.   SCANDINAVIAN JOURNAL OF RHEUMATOLOGY

Baseline levels of soluble interleukin-6 receptor predict clinical remission in patients with rheumatoid arthritis treated with tocilizumab: implications for molecular targeted therapy

(2013) Naoshi Nishina et al.   ANNALS OF THE RHEUMATIC DISEASES

Interleukin-6 Receptor Blockade Selectively Reduces IL-21 Production by CD4 T Cells and IgG4 Autoantibodies in Rheumatoid Arthritis

(2013) Gustavo Carbone et al.   International Journal of Biological Sciences

Serum Interleukin 6 Before and After Therapy with Tocilizumab Is a Principal Biomarker in Patients with Rheumatoid Arthritis

(2013) K. Shimamoto et al.   JOURNAL OF RHEUMATOLOGY

Predictors of response and remission in a large cohort of rheumatoid arthritis patients treated with tocilizumab in clinical practice

(2013) Yves-Marie Pers et al.   RHEUMATOLOGY

Incomplete response of inflammatory arthritis to TNFα blockade is associated with the Th17 pathway

(2012) Saba Alzabin et al.   ANNALS OF THE RHEUMATIC DISEASES

Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study

(2012) Mark C Genovese et al.   ANNALS OF THE RHEUMATIC DISEASES

Targeting Interleukin-6: All the Way to Treat Autoimmune and Inflammatory Diseases

(2012) Toshio Tanaka et al.   International Journal of Biological Sciences

Elevated Levels of T Helper 17 Cells Are Associated with Disease Activity in Patients with Rheumatoid Arthritis

(2012) Jimyung Kim et al.   Annals of Laboratory Medicine

Rheumatoid arthritis subgroup with type I interferon signature: Comment on the article by Thurlings et al

(2011) Jin Kyun Park   ARTHRITIS AND RHEUMATISM

Increasing levels of circulating Th17 cells and interleukin-17 in rheumatoid arthritis patients with an inadequate response to anti-TNF-α therapy

(2011) Der-Yuan Chen et al.   ARTHRITIS RESEARCH & THERAPY

Effectiveness and safety of the interleukin 6-receptor antagonist tocilizumab after 4 and 24 weeks in patients with active rheumatoid arthritis: the first phase IIIb real-life study (TAMARA)

(2010) G. R. Burmester et al.   ANNALS OF THE RHEUMATIC DISEASES

Relationship between the type I interferon signature and the response to rituximab in rheumatoid arthritis patients

(2010) Rogier M. Thurlings et al.   ARTHRITIS AND RHEUMATISM

Th17 cells, but not Th1 cells, from patients with early rheumatoid arthritis are potent inducers of matrix metalloproteinases and proinflammatory cytokines upon synovial fibroblast interaction, including autocrine interleukin-17A production

(2010) J. P. van Hamburg et al.   ARTHRITIS AND RHEUMATISM

Evidence for the role of Th17 cell inhibition in the prevention of autoimmune diseases by anti-interluekin-6 receptor antibody

(2009) Masahiko Mihara et al.   BIOFACTORS

Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study

(2008) N Nishimoto et al.   ANNALS OF THE RHEUMATIC DISEASES

Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: The tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study

(2008) Mark C. Genovese et al.   ARTHRITIS AND RHEUMATISM

Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial

(2008) Josef S Smolen et al.   LANCET